Idebenone

Idebenone
Clinical data
Trade names	Catena, Raxone, Sovrima
AHFS/Drugs.com	International Drug Names
Routes of; administration	By mouth
ATC code	N06BX13 (WHO) ;
Legal status
Legal status	EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	<1% (high first pass effect)
Protein binding	>99%
Elimination half-life	18 hours
Excretion	Urine (80%) and feces
Identifiers
	IUPAC name 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-; cyclohexa-2,5-diene-1,4-dione;
CAS Number	58186-27-9 ;
PubChem CID	3686;
ChemSpider	3558 ;
UNII	HB6PN45W4J;
KEGG	D01750 ;
ChEBI	CHEBI:31687;
ChEMBL	ChEMBL252556 ;
CompTox Dashboard (EPA)	DTXSID0040678 ;
Chemical and physical data
Formula	C19H30O5
Molar mass	338.444 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C1/C(=C(\C(=O)C(\OC)=C1\OC)C)CCCCCCCCCCO;
	InChI InChI=1S/C19H30O5/c1-14-15(12-10-8-6-4-5-7-9-11-13-20)17(22)19(24-3)18(23-2)16(14)21/h20H,4-13H2,1-3H3 ; Key:JGPMMRGNQUBGND-UHFFFAOYSA-N ;
	(verify)

Idebenone, sold under the brand name Raxone among others, is a medication that was initially developed by Takeda Pharmaceutical Company for the treatment of Alzheimer's disease and other cognitive defects. This has been met with limited success. The Swiss company Santhera Pharmaceuticals has started to investigate it for the treatment of neuromuscular diseases. In 2010, early clinical trials for the treatment of Friedreich's ataxia and Duchenne muscular dystrophy have been completed. As of December 2013 the drug is not approved for these indications in North America or Europe. It is approved by the European Medicines Agency (EMA) for use in Leber's hereditary optic neuropathy (LHON) and was designated an orphan drug in 2007.

Chemically, idebenone is an organic compound of the quinone family. It is also promoted commercially as a synthetic analog of coenzyme Q₁₀ (CoQ₁₀).